Brain cancer study receives CIHR/NSERC funding
A national multidisciplinary team lead by Dr. Donald Miller, an Associate Professor in Pharmacology & Therapeutics at the University of Manitoba and Principal Investigator at the Kleysen Institute for Advanced Medicine, Health Sciences Centre Winnipeg, was recently awarded a CIHR/NSERC Collaborative Health Research Project grant worth $753K over a 3 year term to study glioblastoma multiforme (GBM). This form of brain cancer is considered to be the most common and aggressive type occurring in adults. It is typically associated with poor patient outcomes and high fatality rates.
The national team also includes other University of Manitoba scientists, including Drs. Thomas Klonisch, Ted Lakowski, and Marshall Pitz, and collaborators from western Canada – Dr. Wishart from the Metabolomics Innovation Centre in Alberta and BioMark Diagnostics in British Columbia.
This collaborative project will assess blood and urine samples for biomarkers that could be used for the early detection and treatment of GBM. Using brain-tumour models in the lab and proof-of-concept clinical studies the team hopes to develop a safe, reliable, and affordable test to monitor the development and progression of brain tumors, which is key to early intervention and improved patient care.
| Contributor | —Crystal Acosta |